Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: A form fruste of myelodysplasia?

Leukemia Research

Volumn 27, Issue 3, 2003, Pages 235-242

  Steensma, David P ^a   Dewald, Gordon W ^b   Hodnefield, Janice M ^b   Tefferi, Ayalew ^a   Hanson, Curtis A ^b  

^a MAYO CLINIC ROCHESTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Bone marrow morphology; Cytogenetics; Cytopenias; Myelodysplasia

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW CELL; BONE MARROW EXAMINATION; CHROMOSOME 13Q; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLONAL VARIATION; CYTOPENIA; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MYELODYSPLASIA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS;

AGED; BONE MARROW; BONE MARROW EXAMINATION; CAUSE OF DEATH; CHROMOSOME ABERRATIONS; CLONE CELLS; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; MALE; MYELODYSPLASTIC SYNDROMES; PANCYTOPENIA; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0037353282     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00161-3     Document Type: Article

References (74)

1. Sole F., Espinet B., Sanz G.F., Cervera J., Calasanz M.J., Luno E.et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes, Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J. Haematol. 108:2000;346-356.
2. Noel P., Tefferi A., Pierre R.V., Jenkins R.B., Dewald G.W. Karyotypic analysis in primary myelodysplastic syndromes. Blood Rev. 7:1993;10-18.
3. Heaney M.L., Golde D.W. Myelodysplasia. N. Engl. J. Med. 340:1999;1649-1660.
4. Mufti G.J. Chromosomal deletions in the myelodysplastic syndrome. Leuk. Res. 16:1992;35-41.
5. Tefferi A., Mesa R.A., Schroeder G., Hanson C.A., Li C.Y., Dewald G.W. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br. J. Haematol. 113:2001;763-771.
6. Dewald G.W., Wright P.I. Chromosome abnormalities in the myeloproliferative disorders. Semin. Oncol. 22:1995;341-354.
7. Diez-Martin J.L., Graham D.L., Petitt R.M., Dewald G.W. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin. Proc. 66:1991;287-299.
8. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 341:1999;1051-1062.
9. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R.et al. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51:1982;189-199.
10. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J.et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. 17:1999;3835-3849.
11. Ong S.T., Le Beau M.M. Chromosomal abnormalities and molecular genetics of non-Hodgkin's lymphoma. Semin. Oncol. 25:1998;447-460.
12. Fonseca R, Coignet LJ, Dewald GW. Cytogenetic abnormalities in multiple myeloma. Part VIII. Hematol Oncol Clin North Am 1999;13:1169-80.
13. Loss of the Y chromosome from normal and neoplastic bone marrows. United Kingdom Cancer Cytogenetics Group (UKCCG). Genes Chromosomes Cancer 1992;5:83-8.
14. Herens C., Brasseur E., Jamar M., Vierset L., Schoenen I., Koulischer L. Loss of the Y chromosome in bone marrow cells: results on 1907 consecutive cases of leukaemia and preleukaemia. Clin. Lab. Haematol. 21:1999;17-20.
15. Pierre R.V., Hoagland H.C. Age-associated aneuploidy: loss of Y chromosome from human bone marrow cells with aging. Cancer. 30:1972;889-894.
16. Appelbaum F.R., Barrall J., Storb R., Ramberg R., Doney K., Sale G.E.et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp. Hematol. 15:1987;1134-1139.
17. Spurbeck J.L., Carlson R.O., Allen J.E., Dewald G.W. Culturing and robotic harvesting of bone marrow, lymph nodes, peripheral blood, fibroblasts, and solid tumors with in situ techniques. Cancer Genet. Cytogenet. 32:1988;59-66.
18. Mitelman F, editor. ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel: Karger, 1995.
19. Falini B., Flenghi L., Pileri S., Gambacorta M., Bigerna B., Durkop H.et al. PG-M1: a new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am. J. Pathol. 142:1993;1359-1372.
20. Yoon S.Y., Li C.Y., Mesa R.A., Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 106:1999;682-688.
21. Hanson C.A., Dayharsh G.A., Morice W.G., Hodnefield J.M., Steensma D.P. Clonal T-cell and immunoglobulin gene rearrangements in myelodysplastic syndromes (MDS): a morphologic and immunoperoxidase study. Leuk. Res. 25:2001;S12-S13.
22. Dunn D.E., Tanawattanacharoen P., Boccuni P., Nagakura S., Green S.W., Kirby M.R.et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann. Intern. Med. 131:1999;401-408.
23. Steensma D.P., Hanson C.A., Letendre L., Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk. Res. 25:2001;829-838.
24. Dewald G.W., Stupca P. 154 chromosome anomalies in hematologic malignancies. Leuk. Res. 24:2000;487-489.
25. Morrison-DeLap S.J., Kuffel D.G., Dewald G.W., Letendre L. Unbalanced 1;7 translocation and therapy-induced hematologic disorders: a possible relationship. Am. J. Hematol. 21:1986;39-47.
26. Kikuchi A., Ohashi H., Hanada R., Yamamoto K. Myelodysplastic syndrome (MDS) with unbalanced t(1;7) after severe aplastic anemia (SAA) in childhood as a variant form of monosomy 7. Leukemia. 12:1998;2036-2038.
27. Davis M.P., Dewald G.W., Pierre R.V., Hoagland H.C. Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet. Cytogenet. 12:1984;63-71.
28. Mathew P., Tefferi A., Dewald G.W., Goldberg S.L., Su J., Hoagland H.C.et al. The 5q-syndrome: a single-institution study of 43 consecutive patients. Blood. 81:1993;1040-1045.
29. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G.et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 89:1997;2079-2088.
30. La Starza R., Wlodarska I., Aventin A., Falzetti D., Crescenzi B., Martelli M.F.et al. Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. Blood. 91:1998;231-237.
31. Olney H.J., Mitelman F., Johansson B., Mrozek K., Berger R., Rowley J.D. Unique balanced chromosome abnormalities in treatment-related myelodysplastic syndromes and acute myeloid leukemia: report from an International Workshop. Genes Chromosomes Cancer. 33:2002;413-423.
32. Block A.W., Carroll A.J., Hagemeijer A., Lm L.M., van Lom K., Olney H.J.et al. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an International Workshop. Genes Chromosomes Cancer. 33:2002;401-412.
33. Mitelman F, Johansson B, Mertens F. Mitelman. Database of chromosome aberrations in cancer, 2001.
34. Dickstein J.I., Vardiman J.W. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am. J. Clin. Pathol. 99:1993;513-525.
35. Kampmeier P., Anastasi J., Vardiman J.W. Issues in the pathology of the myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 6:1992;501-522.
36. Greenberg P., Anderson J., de Witte T., Estey E., Fenaux P., Gupta P.et al. Problematic WHO reclassification of myelodysplastic syndromes: members of the International MDS Study Group. J. Clin. Oncol. 18:2000;3447-3452.
37. Tricot G.J. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk. Res. 16:1992;5-6.
38. Lichtman M.A. Myelodysplasia or myeloneoplasia: thoughts on the nosology of clonal myeloid diseases. Blood Cells Mol. Dis. 26:2000;572-581.
39. Kuffel D.G., Schultz C.G., Ash R.C., Dewald G.W. Normal cytogenetic values for bone marrow based on studies of bone marrow transplant donors. Cancer Genet. Cytogenet. 55:1991;39-48.
40. Raynaud S.D., Brunet B., Chischportich M., Bayle J., Gratecos N., Pesce A.et al. Recurrent cytogenetic abnormalities observed in complete remission of acute myeloid leukemia do not necessarily mark preleukemic cells. Leukemia. 8:1994;245-249.
41. Abruzzese E., Radford J.E., Miller J.S., Vredenburgh J.J., Rao P.N., Pettenati M.J.et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 94:1999;1814-1819.
42. Yunis J.J. Recurrent chromosomal defects are found in most patients with acute non-lymphocytic leukemia. Cancer Genet. Cytogenet. 11:1984;125-137.
43. Keung Y.K., Pettenati M.J., Cruz J.M., Powell B.L., Woodruff R.D., Buss D.H. Bone marrow cytogenetic abnormalities of aplastic anemia. Am. J. Hematol. 66:2001;167-171.
44. Suzan F., Terre C., Garcia I., Bastie J., Baumelou E., Gluckman E.et al. Three cases of typical aplastic anemia associated with a Philadelphia chromosome. Br. J. Haematol. 112:2001;385-387.
45. Jameel T., Anwar M., Abdi S.I., Saleem M., Ahmad P.A., Khattak M.F. Aplastic anemia or aplastic preleukemic syndrome? Ann. Hematol. 75:1997;189-193.
46. Narayanan M.N., Geary C.G., Freemont A.J., Kendra J.R. Long-term follow-up of aplastic anemia. Br. J. Haematol. 86:1994;837-843.
47. Longo L., Bessler M., Beris P., Swirsky D., Luzzatto L. Myelodysplasia in a patient with preexisting paroxysmal nocturnal haemoglobinuria: a clonal disease originating from within a clonal disease. Br. J. Haematol. 87:1994;401-403.
48. van Kamp H., Smit J.W., van den Berg E., Ruud Halie M., Vellenga E. Myelodysplasia following paroxysmal nocturnal haemoglobinuria: evidence for the emergence of a separate clone. Br. J. Haematol. 87:1994;399-400.
49. Jin J.Y., Tooze J.A., Marsh J.C., Matthey F., Gordon-Smith E.C. Myelodysplasia following aplastic anemia-paroxysmal nocturnal haemoglobinuria syndrome after treatment with immunosuppression and G-CSF: evidence for the emergence of a separate clone. Br. J. Haematol. 94:1996;510-512.
50. Barrett J. Myelodysplastic syndrome and aplastic anemia-diagnostic and conceptual uncertainties. Leuk. Res. 24:2000;595-596.
51. Kurtin P.J., Dewald G.W., Shields D.J., Hanson C.A. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. Am. J. Clin. Pathol. 106:1996;680-688.
52. Pedersen-Bjergaard J., Pedersen M., Roulston D., Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 86:1995;3542-3552.
53. Tricot G., Criel A., Verwilghen R.L. Thrombocytopenia as presenting symptom of preleukaemia in three patients. Scand. J. Haematol. 28:1982;243-250.
54. Menke D.M., Colon-Otero G., Cockerill K.J., Jenkins R.B., Noel P., Pierre R.V. Refractory thrombocytopenia: a myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am. J. Clin. Pathol. 98:1992;502-510.
55. George J.N., Woolf S.H., Raskob G.E., Wasser J.S., Aledort L.M., Ballem P.J.et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 88:1996;3-40.
56. Michels S.D., Saumur J., Arthur D.C., Robison L.L., Brunning R.D. Refractory anemia with excess of blasts in transformation hematologic and clinical study of 52 patients. Cancer. 64:1989;2340-2346.
57. Jonveaux P., Fenaux P., Berger R. Trisomy 6 as the sole chromosome abnormality in myeloid disorders. Cancer Genet. Cytogenet. 74:1994;150-152.
58. Horton Y.M., Johnson P.R. Trisomy 14 in myeloid malignancies: report of two cases and review of the literature. Cancer Genet. Cytogenet. 124:2001;172-174.
59. Batanian J.R., Slovak M.L., Mohamed A., Dobin S., Luthardt F.W., Keitges E.A. Trisomy 15 is frequently observed as a minor clone in patients with anemia/MDS/NHL and as a major clone in patients with AML. Cancer Genet. Cytogenet. 121:2000;186-189.
60. Geddes A.A., Bowen D.T., Jacobs A. Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. Br. J. Haematol. 76:1990;194-202.
61. Kocova M.J., Sandberg A.A. Major karyotypic abnormalities in a near-tetraploid erythroleukemia. Cancer Genet. Cytogenet. 17:1985;143-150.
62. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G.et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial, The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 92:1998;2322-2333.
63. Lunde J.H., Allen E.F. Interstitial 9q-deletion in a case of acute myeloid leukemia-M2 arising from a granulocytic sarcoma. Cancer Genet. Cytogenet. 78:1994;239-241.
64. Moir D.J., Jones P.A., Pearson J., Duncan J.R., Cook P., Buckle V.J. A new translocation, t(1;3)(p36;q21), in myelodysplastic disorders. Blood. 64:1984;553-555.
65. Mogul M.J., Brady K., Brothman A.R., Adams R., Peterson F.B., Beatty P.G. Myelodysplastic syndrome presenting with clonal rearrangement isolated to chromosomal region 1q. Cancer Genet. Cytogenet. 95:1997;210-212.
66. Aventin A., La Starza R., Martinez C., Wlodarska I., Boogaerts M., Van den Berghe H. Involvement of MLL gene in a t(10;11)(q22;q23) and a t(8;11)(q24;q23) identified by fluorescence in situ hybridization. Cancer Genet. Cytogenet. 108:1999;48-52.
67. Werner M., Maschek H., Kaloutsi V., Choritz H., Georgii A. Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance. Virchows Arch. A Pathol. Anat. Histopathol. 421:1992;47-52.
68. Inaba T., Hayashi Y., Hanada R., Nakashima M., Yamamoto K., Nishida T. Childhood myelodysplastic syndromes with 11p15 translocation. Cancer Genet. Cytogenet. 34:1988;41-46.
69. Chen Z., Richkind K., Roherty S., Velasco J., Lytle C., Brothman A.R.et al. A group of previously not recognized cytogenetic abnormalities in myeloid hematological malignancies. Cancer Genet. Cytogenet. 113:1999;162-165.
70. Secker-Walker L.M., Moorman A.V., Bain B.J., Mehta A.B. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities: EU concerted action 11q23 workshop. Leukemia. 12:1998;840-844.
71. Shi G., Weh H.J., Martensen S., Seeger D., Hossfeld D.K. 3p21 is a recurrent treatment-related breakpoint in myelodysplastic syndrome and acute myeloid leukemia. Cytogenet. Cell Genet. 74:1996;295-299.
72. Benitez J., Carbonell F., Ferro T., Prieto F., Sanchez Fayos J. Cytogenetic studies in 18 patients with secondary blood disorders. Cancer Genet. Cytogenet. 22:1986;309-317.
73. Dewald G.W., Brecher M., Travis L.B., Stupca P.J. Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts. Cancer Genet. Cytogenet. 42:1989;173-185.
74. Dewald G.W., Pierre R.V., Phyliky R.L. Three patients with structurally abnormal X chromosomes, each with Xq13 breakpoints and a history of idiopathic acquired sideroblastic anemia. Blood. 59:1982;100-105.